Table 6.
Mutations lowering levels of other integral U1 or U2 snRNP proteins do not suppress snf+ dose effects on SxlM12/Y male viability
| Progeny class (Cross†) | Experimental males
|
Control Sxl+ male sibs*, n | |||
|---|---|---|---|---|---|
| Sxl allele | snRNP locus genotype | P{snf+} copies | Relative viability | ||
| 1 (A) | SxlM12 | U1-70K62/U1-70K62 | 1 | 1% | 71 |
| 2 (A) | SxlM12 | +/+ | 0 | 84% | 117 |
| 3 (A) | Sxl+ | U1-70K62/U1-70K62 | 1 | 44% | 161 |
| 4 (B) | SxlM12 | noi2/Df(noi) | 1 | 0% | 240 |
| 5 (B) | SxlM12 | noi2/Df(noi) | 0 | 80% | 225 |
| 6 (B) | Sxl+ | noi2/Df(noi) | 1 | 90% | 267 |
For classes 3 and 6, these are U1-70K62/+ and noi2/+, respectively. For all others, autosomal genotypes match experimentals. Sxl genotype was inferred from the closely linked (0.9 cM) ct marker, except that rare Sxl+-ct recombinants were recognized by their lack of the abdominal etching diagnostic for SxlM12.
† A, w SxlM12ct6/w; U1-70K62/SM6b, Cy Roi ☿☿ × ♂♂ w/Y; U1-70K62 P{snf+w+mC}108/+. B, w SxlM12ct6/w; noi2{PlacW,w+mC}/TM2, Ubx ☿☿ × ♂♂ w/Y; P{snf+w+mC}108/+; Df(3R)noi-D/st Ki pp ry.